NASDAQ:STIM - Neuronetics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $14.50 -2.20 (-13.17 %) (As of 03/22/2019 04:00 PM ET)Previous Close$16.70Today's Range$14.40 - $16.6052-Week Range$13.26 - $39.39Volume133,900 shsAverage Volume142,155 shsMarket Capitalization$261.80 millionP/E Ratio-5.39Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania. Receive STIM News and Ratings via Email Sign-up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STIM Previous Symbol CUSIPN/A CIKN/A Webwww.neuronetics.com Phone610-640-4202Debt Debt-to-Equity Ratio0.43 Current Ratio8.44 Quick Ratio8.26Price-To-Earnings Trailing P/E Ratio-5.39 Forward P/E Ratio-8.90 P/E GrowthN/A Sales & Book Value Annual Sales$52.78 million Price / Sales4.96 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book3.59Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares18,055,000Market Cap$261.80 million Next Earnings Date6/4/2019 (Estimated) OptionableNot Optionable Neuronetics (NASDAQ:STIM) Frequently Asked Questions What is Neuronetics' stock symbol? Neuronetics trades on the NASDAQ under the ticker symbol "STIM." How were Neuronetics' earnings last quarter? Neuronetics Inc (NASDAQ:STIM) released its quarterly earnings results on Tuesday, March, 5th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.01. View Neuronetics' Earnings History. When is Neuronetics' next earnings date? Neuronetics is scheduled to release their next quarterly earnings announcement on Tuesday, June 4th 2019. View Earnings Estimates for Neuronetics. What guidance has Neuronetics issued on next quarter's earnings? Neuronetics issued an update on its first quarter 2019 earnings guidance on Tuesday, March, 5th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $12.4-13 million, compared to the consensus revenue estimate of $13.01 million.Neuronetics also updated its FY 2019 guidance to EPS. What price target have analysts set for STIM? 5 equities research analysts have issued 12 month target prices for Neuronetics' shares. Their predictions range from $25.00 to $40.00. On average, they anticipate Neuronetics' share price to reach $32.25 in the next year. This suggests a possible upside of 122.4% from the stock's current price. View Analyst Price Targets for Neuronetics. What is the consensus analysts' recommendation for Neuronetics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neuronetics. What are Wall Street analysts saying about Neuronetics stock? Here are some recent quotes from research analysts about Neuronetics stock: 1. BTIG Research analysts commented, "$25 PT Neuronetics reported 4Q18 results with both capital sales and treatment revenue surpassing our forecast. Ending BDM count was in-line with expectations, implying rep productivity is ahead of planned (mgmt confirmed the same). Looking ahead to FY19, top-line guidance brackets current Street estimates. Mgmt is assuming more rep hires than the Street, driving up the operating expense outlook. On underlying assumptions, mgmt appears to be basing forecasts on historical productivity metrics instead of more recent encouraging trends likely creating upside. Additionally, the company does not appear to be aggressively signaling gross margin expansion though we still feel a greater mix of higher-margin consumable sales should push this metric higher." (3/6/2019) 2. According to Zacks Investment Research, "Neuronetics, Inc. is a commercial-stage medical device company. It focused on designing, developing, and marketing products for patients who suffer from psychiatric disorders. NeuroStar Advanced Therapy System(R), is the transcranial magnetic stimulation treatment for depressive disorder. Neuronetics, Inc. is based in Malvern, United States. " (11/10/2018) Has Neuronetics been receiving favorable news coverage? News stories about STIM stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neuronetics earned a daily sentiment score of -1.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the near future. Who are some of Neuronetics' key competitors? Some companies that are related to Neuronetics include K2M Group (KTWO), Tactile Systems Technology (TCMD), AtriCure (ATRC), Luminex (LMNX), Orthofix Medical (OFIX), Cryolife (CRY), Intersect ENT (XENT), Cerus (CERS), AngioDynamics (ANGO), Axonics Modulation Technologies (AXNX), OraSure Technologies (OSUR), Orthopediatrics (KIDS), LeMaitre Vascular (LMAT), SurModics (SRDX) and Antares Pharma (ATRS). What other stocks do shareholders of Neuronetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include Progenics Pharmaceuticals (PGNX), Anavex Life Sciences (AVXL), Cidara Therapeutics (CDTX), Portola Pharmaceuticals (PTLA), Madrigal Pharmaceuticals (MDGL), CytomX Therapeutics (CTMX), Axsome Therapeutics (AXSM), Tonix Pharmaceuticals (TNXP), Adamis Pharmaceuticals (ADMP) and Five Prime Therapeutics (FPRX). Who are Neuronetics' key executives? Neuronetics' management team includes the folowing people: Mr. Christopher A. Thatcher, CEO, Pres & Director (Age 54)Mr. Peter L. Donato, VP of Fin. & CFO (Age 49)Mr. Gregory Harper, VP of R&D, Operations and Product Devel. (Age 58)Mr. Stephen MacKinnon, VP of SalesMs. Cassie Hallberg, VP of Marketing When did Neuronetics IPO? (STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers. Who are Neuronetics' major shareholders? Neuronetics' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.48%), Lord Abbett & CO. LLC (2.43%), FMR LLC (1.28%), RTW Investments LP (0.95%), Bellevue Group AG (0.94%) and United Services Automobile Association (0.44%). Company insiders that own Neuronetics stock include Daniel Guthrie, Peter Donato and Wilfred E Jaeger. View Institutional Ownership Trends for Neuronetics. Which institutional investors are selling Neuronetics stock? STIM stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Northern Trust Corp and Barclays PLC. View Insider Buying and Selling for Neuronetics. Which institutional investors are buying Neuronetics stock? STIM stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Bellevue Group AG, Partner Fund Management L.P., United Services Automobile Association, Millennium Management LLC, Virtus ETF Advisers LLC, Geode Capital Management LLC and Geode Capital Management LLC. Company insiders that have bought Neuronetics stock in the last two years include Daniel Guthrie and Wilfred E Jaeger. View Insider Buying and Selling for Neuronetics. How do I buy shares of Neuronetics? Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Neuronetics' stock price today? One share of STIM stock can currently be purchased for approximately $14.50. How big of a company is Neuronetics? Neuronetics has a market capitalization of $261.80 million and generates $52.78 million in revenue each year. The company earns $-24,100,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. What is Neuronetics' official website? The official website for Neuronetics is http://www.neuronetics.com. How can I contact Neuronetics? Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected] MarketBeat Community Rating for Neuronetics (NASDAQ STIM)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 42 (Vote Outperform)Underperform Votes: 34 (Vote Underperform)Total Votes: 76MarketBeat's community ratings are surveys of what our community members think about Neuronetics and other stocks. Vote "Outperform" if you believe STIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STIM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/23/2019 by MarketBeat.com StaffFeatured Article: Why do companies pay special dividends?